SAD and MAD Study of AKB-9090 in Healthy Adult Participants
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Healthy Volunteers
In brief
This is a first-in-human (FIH study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic effects of AKB-9090 in healthy adult participants. The study consists of two stages: Stage 1, a single ascending dose (SAD) phase with five dose cohorts, and Stage 2, a multiple ascending dose (MAD) phase with three dose cohorts. Approximately 40 participants in SAD and 30 in MAD are planned to be enrolled.
Key facts
- Study ID
- NCT07429006
- Run by
- Akebia Therapeutics
- People needed
- 70
- Starts
- 2026-03-16
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-04-13
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.
Where it is running
- Investigator Site #1 — Auckland, New Zealand (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.